28323937|t|TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease
28323937|a|Little is known about the frequency of key mutations in thyroid cancer metastases and its relationship with the primary tumor genotype. To evaluate the frequency of TERT promoter (TERTp), BRAF and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNM) and distant metastases. Mutation analysis was performed in 437 tissue samples from 204 patients, mainly with papillary thyroid carcinomas (PTC) (n=180), including 196 LNM and 56 distant metastases. All the distant metastases included corresponded to radioiodine -refractory metastatic tissue. We found the following mutation frequency in primary PTC, LNM and distant metastases, respectively: TERTp - 12.9%, 10.5%, and 52.4%; BRAF - 44.6%, 41.7%, and 23.8%; NRAS - 1.2%, 1.3%, and 14.3%. There was a significant concordance between the primary tumor genotype and the corresponding LNM for all the genes, in particular BRAF -mutated PTC. The overall concordance between primary tumors and respective distant metastases was low. In the group of patients with PTC, we found a high frequency of TERTp mutations and a low frequency of BRAF mutations in distant metastases, in comparison to the paired primary tumors. When present in distant metastases, BRAF mutations frequently coexisted with TERTp mutations. When the genotype of primary tumors is compared with the genotype of LNM, the concordance is high for all the genes studied. On the other hand, distant metastases show an enrichment in TERTp mutations and a decrease in BRAF mutations. TERTp mutations may play a role in distant metastases.
28323937	0	4	TERT	T103	UMLS:C0754515
28323937	6	10	BRAF	T103	UMLS:C1259929
28323937	15	19	NRAS	T103	UMLS:C0079975
28323937	50	68	metastatic disease	T038	UMLS:C0027627
28323937	125	139	thyroid cancer	T038	UMLS:C0007115
28323937	140	150	metastases	T038	UMLS:C0027627
28323937	181	194	primary tumor	T038	UMLS:C0677930
28323937	234	238	TERT	T017	UMLS:C1367342
28323937	239	247	promoter	T017	UMLS:C0314621
28323937	249	254	TERTp	T017	UMLS:C0314621
28323937	257	261	BRAF	T017	UMLS:C0812241
28323937	266	270	NRAS	T017	UMLS:C0027260
28323937	271	280	mutations	T038	UMLS:C1516197
28323937	284	294	metastatic	T038	UMLS:C0027627
28323937	295	313	thyroid carcinomas	T038	UMLS:C0549473
28323937	349	370	lymph node metastases	T038	UMLS:C0686619
28323937	372	375	LNM	T038	UMLS:C0686619
28323937	381	399	distant metastases	T170	UMLS:C1269798
28323937	401	418	Mutation analysis	T058	UMLS:C0796357
28323937	440	454	tissue samples	T017	UMLS:C0475358
28323937	486	514	papillary thyroid carcinomas	T038	UMLS:C0238463
28323937	516	519	PTC	T038	UMLS:C0238463
28323937	544	547	LNM	T038	UMLS:C0686619
28323937	555	573	distant metastases	T170	UMLS:C1269798
28323937	583	601	distant metastases	T170	UMLS:C1269798
28323937	627	638	radioiodine	T103	UMLS:C1441129
28323937	651	661	metastatic	T038	UMLS:C0027627
28323937	662	668	tissue	T017	UMLS:C0040300
28323937	715	722	primary	T038	UMLS:C0677930
28323937	723	726	PTC	T038	UMLS:C0238463
28323937	728	731	LNM	T038	UMLS:C0686619
28323937	736	754	distant metastases	T170	UMLS:C1269798
28323937	770	775	TERTp	T017	UMLS:C0314621
28323937	803	807	BRAF	T017	UMLS:C0812241
28323937	835	839	NRAS	T017	UMLS:C0027260
28323937	913	926	primary tumor	T038	UMLS:C0677930
28323937	958	961	LNM	T038	UMLS:C0686619
28323937	974	979	genes	T017	UMLS:C0017337
28323937	995	999	BRAF	T017	UMLS:C0812241
28323937	1009	1012	PTC	T038	UMLS:C0238463
28323937	1046	1060	primary tumors	T038	UMLS:C0677930
28323937	1076	1094	distant metastases	T170	UMLS:C1269798
28323937	1134	1137	PTC	T038	UMLS:C0238463
28323937	1168	1173	TERTp	T017	UMLS:C0314621
28323937	1174	1183	mutations	T038	UMLS:C1516197
28323937	1207	1211	BRAF	T017	UMLS:C0812241
28323937	1212	1221	mutations	T038	UMLS:C1516197
28323937	1225	1243	distant metastases	T170	UMLS:C1269798
28323937	1273	1287	primary tumors	T038	UMLS:C0677930
28323937	1305	1323	distant metastases	T170	UMLS:C1269798
28323937	1325	1329	BRAF	T017	UMLS:C0812241
28323937	1330	1339	mutations	T038	UMLS:C1516197
28323937	1366	1371	TERTp	T017	UMLS:C0314621
28323937	1372	1381	mutations	T038	UMLS:C1516197
28323937	1404	1418	primary tumors	T038	UMLS:C0677930
28323937	1452	1455	LNM	T038	UMLS:C0686619
28323937	1493	1498	genes	T017	UMLS:C0017337
28323937	1527	1545	distant metastases	T170	UMLS:C1269798
28323937	1568	1573	TERTp	T017	UMLS:C0314621
28323937	1574	1583	mutations	T038	UMLS:C1516197
28323937	1602	1606	BRAF	T017	UMLS:C0812241
28323937	1607	1616	mutations	T038	UMLS:C1516197
28323937	1618	1623	TERTp	T017	UMLS:C0314621
28323937	1624	1633	mutations	T038	UMLS:C1516197
28323937	1653	1671	distant metastases	T170	UMLS:C1269798